kabutan

SymBio Pharmaceuticals Limited(4582) Summary

4582
TSE Growth
SymBio Pharmaceuticals Limited
98
JPY
-2
(-2.00%)
Dec 12, 3:30 pm JST
0.62
USD
Dec 12, 1:30 am EST
Result
PTS
outside of trading hours
98.3
Dec 12, 11:15 pm JST
Summary Chart Historical News Financial Result
PER
PBR
4.03
Yield
ー%
Margin Trading Ratio
11,263.25
Stock Price
Dec 12, 2025
Opening Dec 12, 9:00 am
99 JPY 0.63 USD
Previous Close Dec 11
100 JPY 0.64 USD
High Dec 12, 9:00 am
100 JPY 0.64 USD
Low Dec 12, 1:15 pm
98 JPY 0.62 USD
Volume
475,100
Trading Value
0.05B JPY 0.30M USD
VWAP
98.94 JPY 0.64 USD
Minimum Trading Value
9,800 JPY 62 USD
Market Cap
5.35B JPY 0.03B USD
Number of Trades
143
Liquidity & Number of Trades
As of Dec 12, 2025
Liquidity
Mid
1-Year Average
261
1-Year High Sep 17, 2025
3,139
Margin Trading
Date Short Interest Long Margin Positions Ratio
Dec 5, 2025 0 3,966,000
Nov 28, 2025 0 4,002,400
Nov 21, 2025 0 4,009,700
Nov 14, 2025 0 4,348,900
Nov 7, 2025 0 4,282,600
Company Profile
SymBio Pharmaceuticals Limited specializes in three areas: cancer, hematology, and pain management. The company also commercializes new drug candidates from other companies.
Sector
Pharmaceuticals
SymBio Pharmaceuticals Limited is a specialty pharmaceutical company focused on rare diseases, primarily in the fields of oncology, hematology, and viral infections. The company advances the development of compounds that have already established proof of concept in humans. Utilizing its unique discovery network and evaluation expertise, SymBio conducts initial screenings through its in-house specialist staff, followed by rigorous evaluations from experienced external experts before finalizing potential in-licensing candidates. By adopting a "labo-less fab-less" strategy to minimize fixed costs, the company concentrates on high-value-added activities while outsourcing routine development tasks. SymBio's pipeline includes drugs such as Treakisym, rigosertib, and brincidofovir, promoting new drug development in areas with high unmet medical needs. While the company has primarily focused its business operations in Japan and Asia, it now aims to expand globally to enhance its business value.